Dino Amadori

Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer.

Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.

Personal use of hair dyes and hematolymphopoietic malignancies.

[Telomerase activity: a molecular marker for early diagnosis of bladder tumor].

Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.

Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis.

Urine telomerase activity for the detection of bladder cancer in females.

Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine.

Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines.

Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.

Disease family history and modification of breast cancer risk in common BRCA2 variants.

Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study.

NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells.

Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells.

Risk of leukemia and multiple myeloma associated with exposure to benzene and other organic solvents: evidence from the Italian Multicenter Case-control study.

Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.

Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.

Activity of lipoplatin in tumor and in normal cells in vitro.

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.

Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

The current role of telomerase in the diagnosis of bladder cancer.

Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model.

A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.

Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.

Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression.

Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.

Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients.

Pathogenesis of osteoblastic bone metastases from prostate cancer.

[18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy.

Modulation of mismatch repair and genomic stability by miR-155.

Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.

Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.

Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals.

Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G).

MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2).

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.

Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.

Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus.

Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer.

Managing chronic pain: results from an open-label study using MC5-A Calmare® device.

Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.

Bone metastases detection by circulating biomarkers: OPG and RANK-L.

Reproducibility of results on chronic pain with MC5-A Calmare® device from independent studies.

GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer.

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.

Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.

The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study.

Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.

Expectations of survivors, caregivers and healthcare providers for testicular cancer survivorship and quality of life.

Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.

Tumorlets in familial history of bronchopulmonary carcinoid.

Detection of HER2 and Topo 2 in breast cancers: comparison between MLPA and FISH approaches.

Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium.

Clinical implications of microRNAs in lung cancer.

Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study.

Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer.

Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity.

Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.

Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care.

Prospective comparison of prognostic scores in palliative care cancer populations.

Palliative sedation in end-of-life care and survival: a systematic review.

Pancreatic resection for metastases from renal cancer: long term outcome after surgery and immunotherapy approach - single center experience.

Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients.

Ipilimumab in advanced melanoma: reports of long-lasting responses.

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.

Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma.

FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy.

Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential.

Perspectives on mTOR inhibitors for castration-refractory prostate cancer.

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.

Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2.

Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data.

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.

Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer.

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer.

miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis.

Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.

Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs.

Multiple marker detection in peripheral blood for NSCLC diagnosis.

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study.

Hemangioblastoma of the gastrointestinal tract: a first case.

Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue.

A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.

Metastatic bone disease in the era of bone-targeted therapy: clinical impact.

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.

Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.

Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC.

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.

Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy?

RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.

Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone).

Biofunctional characteristics of in situ and invasive breast carcinoma.

Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy.

What can we learn from the ZOOM trial?--Authors' reply.

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).

Bone and cancer: the osteoncology.

Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis.

A new emergency in oncology: Bone metastases in breast cancer patients (Review).

Salvage treatment of relapsed or refractory germ-cell tumours.

Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.

DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach.

Retrospective analysis on the management of metastatic gastric cancer patients. A mono-institutional experience. What happens in clinical practice?

Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.

Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.

Benefit from anthracyclines in relation to biological profiles in early breast cancer.

EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?

Is a clear benefit in survival enough to modify patient access to the surgery service? A retrospective analysis in a cohort of gastric cancer patients.

Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.

Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers.

Targeting bone metastatic cancer: Role of the mTOR pathway.

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study.

The emerging role of anti-angiogenic therapy in ovarian cancer (review).

MicroRNAs and dendritic cell-based vaccination in melanoma patients.

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).

Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation.

Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.

Erratum to: Is a clear benefit in survival enough to modify patient access to the surgery service? A retrospective analysis in a cohort of gastric cancer patients.

Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.

CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.

The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin.

First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer.

Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients.

Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy.

Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue.

Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence.

Improved stool DNA integrity method for early colorectal cancer diagnosis.

ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling.

Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide.

Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report.

Clinical and genetic factors related to cancer-induced bone pain and bone pain relief.

Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients?

Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.

Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer.

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.

Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.

Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?

A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab.

(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

Uncovering the genomic heterogeneity of multifocal breast cancer.

Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.

Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.

Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast.

IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia.

Circulating tumor cells in early breast cancer: A connection with vascular invasion.

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.

Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.

Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.

Plasma AR and abiraterone-resistant prostate cancer.

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.

Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial.

The Mwanza Cancer Project.

Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study.

Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report.

Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.

The Comprehensive Cancer Care Network of Romagna: the opportunities generated by the OECI accreditation program.

Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer.

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.

Patterns and determinants of receipt of follow-up mammography and/or clinical examination in a cohort of Italian breast cancer survivors.

Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.

Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial.

Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.

Androgen receptor signaling pathways as a target for breast cancer treatment.

Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model.

Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).

[Corrigendum] Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines.

RANKL: A promising circulating marker for bone metastasis response.

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.

Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.

Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of (18)FDG-PET/CT.

Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway.

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.

Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.

CORRECTION: Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Sorafenib for the treatment of breast cancer.

Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.

Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.

Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania.

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.

The challenge of sustainability in healthcare systems: Frequency and cost of inappropriate patterns of breast cancer care (the E.Pic.A study).

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.

Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition.

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.

Management and potentialities of primary cancer cultures in preclinical and translational studies.

Primary leiomyosarcoma of the bone: a case report and a review of the literature.

Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature.

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.

Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.

Myxofibrosarcoma primary cultures: molecular and pharmacological profile.